AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21764136 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX implant 0.7 mg (n = 341)
Number of subjects: 1256
Study 21764136 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX implant 0.35 mg (n = 412)
Number of subjects: 1256
Study 21764136 — intervention group
Group type: COMPARATOR
Intervention: Sham (n = 423)
Number of subjects: 1256
Study 19454187 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with type 1 diabetes (T1D)
Number of subjects: 25
Study 19454187 — intervention group
Group type: COMPARATOR
Intervention: Healthy children (control group)
Number of subjects: 25
Study 16684170 — intervention group
Group type: COMPARATOR
Intervention: Written materials on sexual dysfunction
Number of subjects: 62
Study 16684170 — intervention group
Group type: EXPERIMENTAL
Intervention: Written materials plus three counselling sessions
Number of subjects: 62
Study 14872476 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg etanercept once weekly
Number of subjects: 420
Study 14872476 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg etanercept twice weekly
Number of subjects: 420
Study 14872476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 12412825 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilidine 50 mg intravenously
Number of subjects: 0
Study 12412825 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilidine 50 mg orally
Number of subjects: 0
Study 12412825 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortilidine 10 mg intravenously
Number of subjects: 0
Study 12412825 — intervention group
Group type: COMPARATOR
Intervention: Tilidine (both oral and intravenous)
Number of subjects: 0
Study 9584558 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-emetic therapy
Number of subjects: 650
Study 9584558 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment on day 3
Number of subjects: 650
Study 9584558 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment on day 8 with 7 day time frame
Number of subjects: 650
Study 7544515 — intervention group
Group type: EXPERIMENTAL
Intervention: Various case definitions of benign prostatic hyperplasia (BPH) based on clinical parameters
Number of subjects: 502
Study 2669225 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice daily)
Number of subjects: 9
Study 2669225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2669225 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 9
Study 183790 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotrophin-(1-23)-tricosipeptide-amide (Acethropan S) at a dosage of 0.5 mg
Number of subjects: 0
Study 183790 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotrophin-(1-23)-tricosipeptide-amide (Acethropan S) at a dosage of 0.25 mg
Number of subjects: 0
Study 183790 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotrophin-(1-23)-tricosipeptide-amide (Acethropan S)
Number of subjects: 0
Study 27904985 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to enhance occupational physicians' guideline adherence
Number of subjects: 3379
Study 27904985 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3379
Study 25965711 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning
Number of subjects: 700
Study 25965711 — intervention group
Group type: COMPARATOR
Intervention: Conventional primary PCI
Number of subjects: 700
Study 22554106 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 60
Study 22554106 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 60
Study 21091135 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic device for robotic-assisted fine-motor training
Number of subjects: 21
Study 19740730 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Skill Acquisition Program (ASAP)
Number of subjects: 0
Study 19740730 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 17926610 — intervention group
Group type: EXPERIMENTAL
Intervention: New Bian-stone therapy
Number of subjects: 240
Study 17926610 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture
Number of subjects: 240
Study 15819300 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin group
Number of subjects: 48
Study 15819300 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 11875680 — intervention group
Group type: COMPARATOR
Intervention: Ayurvedic cutting seton (C)
Number of subjects: 108
Study 11875680 — intervention group
Group type: COMPARATOR
Intervention: Conventional fistulotomy (F)
Number of subjects: 108
Study 11875680 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (F and C)
Number of subjects: 108
Study 9046395 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded acrylic expander
Number of subjects: 14
Study 9046395 — intervention group
Group type: COMPARATOR
Intervention: Hyrax appliance
Number of subjects: 14
Study 7943082 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm labor group
Number of subjects: 42
Study 7943082 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature rupture of membranes group
Number of subjects: 42
Study 7943082 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 30871361 — intervention group
Group type: EXPERIMENTAL
Intervention: Monacolin K-rich RYR
Number of subjects: 50
Study 30871361 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA-rich RYR
Number of subjects: 50
Study 30871361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28721957 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular users of MDM Programme
Number of subjects: 322
Study 28721957 — intervention group
Group type: COMPARATOR
Intervention: Occasional/never users of MDM Programme
Number of subjects: 322
Study 28721957 — intervention group
Group type: EXPERIMENTAL
Intervention: Children born with <2.5 kg
Number of subjects: 322
Study 25469829 — intervention group
Group type: EXPERIMENTAL
Intervention: 33G needle
Number of subjects: 87
Study 25469829 — intervention group
Group type: COMPARATOR
Intervention: 32G needle
Number of subjects: 87
Study 22925113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injection (2 mg/0.08 mL)
Number of subjects: 22
Study 22925113 — intervention group
Group type: COMPARATOR
Intervention: No medical treatment (Control)
Number of subjects: 22
Study 21831512 — intervention group
Group type: EXPERIMENTAL
Intervention: PSD503 (phenylephrine 20%, w/w)
Number of subjects: 12
Study 21831512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18082208 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily cotrimoxazole
Number of subjects: 225
Study 18082208 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 225
Study 17415419 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 0
Study 17415419 — intervention group
Group type: COMPARATOR
Intervention: Routine drug therapy
Number of subjects: 0
Study 14520029 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined manipulation, stabilizing exercises, and physician consultation
Number of subjects: 204
Study 14520029 — intervention group
Group type: COMPARATOR
Intervention: Physician consultation alone
Number of subjects: 204
Study 10631856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 59
Study 10631856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 9180313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cement gun technique
Number of subjects: 50
Study 9180313 — intervention group
Group type: COMPARATOR
Intervention: Finger-packing technique
Number of subjects: 50
Study 9180313 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory model (not specified as intervention or control)
Number of subjects: 50
Study 1489026 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural infusion of lignocaine 0.75% after an initial dose of 10 ml of lignocaine 1.5%
Number of subjects: 86
Study 1489026 — intervention group
Group type: COMPARATOR
Intervention: Extradural infusion of bupivacaine 0.125% after an initial dose of 10 ml of bupivacaine 0.25%
Number of subjects: 86
Study 2412043 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg twice daily
Number of subjects: 17
Study 2412043 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets twice daily
Number of subjects: 17
Study 30536638 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (subcutaneous administration)
Number of subjects: 0
Study 30431325 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual laboratory
Number of subjects: 63
Study 30431325 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended group
Number of subjects: 63
Study 30431325 — intervention group
Group type: COMPARATOR
Intervention: Living tissue laboratory
Number of subjects: 63
Study 30431325 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended style
Number of subjects: 63
Study 27378612 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pump therapy
Number of subjects: 758
Study 27378612 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intraaortic balloon pump therapy)
Number of subjects: 758
Study 25047592 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 197
Study 25047592 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC) followed by Azathioprine (AZA)
Number of subjects: 197
Study 25047592 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label RTX
Number of subjects: 197
Study 22267573 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (therapeutic exercises)
Number of subjects: 0
Study 22267573 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard group (no additional exercises)
Number of subjects: 0
Study 22267573 — intervention group
Group type: COMPARATOR
Intervention: Non-injured control group
Number of subjects: 0
Study 22267573 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard group vs Non-injured control group
Number of subjects: 0
Study 22267573 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group vs Non-injured control group
Number of subjects: 0
Study 20070145 — intervention group
Group type: EXPERIMENTAL
Intervention: Feldenkrais exercises (FG group, n = 25)
Number of subjects: 47
Study 20070145 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n = 22)
Number of subjects: 47
Study 17426300 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 20000000
Study 17426300 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Number of subjects: 20000000
Study 17426300 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled dry powdered insulin (IDPI)
Number of subjects: 20000000
Study 15618027 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 20 mg bid
Number of subjects: 20
Study 15618027 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg bid
Number of subjects: 20
Study 15618027 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 25 mg bid
Number of subjects: 20
Study 15618027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12503340 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg i.v. or p.o. twice daily (400 mg twice daily for uncomplicated skin and skin-structure infections)
Number of subjects: 0
Study 12503340 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 0
Study 10455471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 2006
Study 10455471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2006
Study 8590781 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured teaching/treatment programme
Number of subjects: 79
Study 8590781 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes treatment (control group)
Number of subjects: 79
Study 2218875 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock-wave lithotripsy plus adjuvant litholytic therapy with ursodeoxycholic acid (UDCA)
Number of subjects: 133
Study 2218875 — intervention group
Group type: COMPARATOR
Intervention: Placebo (extracorporeal shock-wave lithotripsy)
Number of subjects: 133
Study 2218875 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA for patients with solitary stones ≤20 mm
Number of subjects: 133
Study 2218875 — intervention group
Group type: COMPARATOR
Intervention: Placebo for patients with solitary stones ≤20 mm
Number of subjects: 133
Study 2218875 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock-wave lithotripsy
Number of subjects: 133
Study 895429 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% O2‐20% N2
Number of subjects: 12
Study 31238871 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered communication and shared decision making intervention
Number of subjects: 0
Study 31238871 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 0
Study 28947022 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC 62.5 mcg
Number of subjects: 338
Study 28947022 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC 125 mcg
Number of subjects: 338
Study 28947022 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC (all doses)
Number of subjects: 338
Study 28947022 — intervention group
Group type: COMPARATOR
Intervention: FF (Control)
Number of subjects: 338
Study 25294090 — intervention group
Group type: EXPERIMENTAL
Intervention: sugar-free Red Bull (sfRB)
Number of subjects: 8
Study 25294090 — intervention group
Group type: EXPERIMENTAL
Intervention: water + 120 mg caffeine
Number of subjects: 8
Study 25294090 — intervention group
Group type: COMPARATOR
Intervention: water + placebo
Number of subjects: 8
Study 23988781 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-pass hemoconcentration (MPH)
Number of subjects: 61
Study 23988781 — intervention group
Group type: COMPARATOR
Intervention: Centrifugation (CF)
Number of subjects: 61
Study 21539731 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-scale living facilities
Number of subjects: 0
Study 21539731 — intervention group
Group type: COMPARATOR
Intervention: Traditional nursing homes
Number of subjects: 0
Study 20057195 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined DAK therapy for obesity (inpatient therapy for 6 weeks followed by home-based outpatient treatment for 10.5 months)
Number of subjects: 162
Study 20057195 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list subjects)
Number of subjects: 162
Study 20057195 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined DAK therapy for obesity
Number of subjects: 162
Study 17413047 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg daily for up to 14 days)
Number of subjects: 80
Study 17413047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 12845405 — intervention group
Group type: EXPERIMENTAL
Intervention: METH (10 mg)
Number of subjects: 28
Study 12845405 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress (Trier Social Stress Test)
Number of subjects: 28
Study 12845405 — intervention group
Group type: COMPARATOR
Intervention: METH (10 mg) with Stress
Number of subjects: 28
Study 12563720 — intervention group
Group type: EXPERIMENTAL
Intervention: Zyrtec (Cetirizine 2 HCL) drops 5 mg daily for 3 weeks
Number of subjects: 47
Study 10170452 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG-CoA reductase inhibitors
Number of subjects: 30
Study 8445848 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily aminoglycosides (tobramycin or netilmicin) - total daily dosage: 4.97 +/- 1.12 mg/kg (total dosage per exacerbation: 74.55 mg/kg)
Number of subjects: 26
Study 8445848 — intervention group
Group type: COMPARATOR
Intervention: Thrice daily aminoglycosides (tobramycin or netilmicin) - total daily dosage: 9.60 +/- 2.70 mg/kg (total dosage per exacerbation: 165.12 mg/kg)
Number of subjects: 26
Study 3522422 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-loaded beer
Number of subjects: 16
Study 31735057 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal and Social Rhythm Therapy
Number of subjects: 100
Study 31735057 — intervention group
Group type: COMPARATOR
Intervention: Non‐specific Supportive Clinical Management
Number of subjects: 100
Study 30229883 — intervention group
Group type: EXPERIMENTAL
Intervention: Pythagorean Self‐Awareness Intervention (PSAI)
Number of subjects: 30
Study 30229883 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 29336896 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with 0.3 mg ranibizumab and TRP
Number of subjects: 40
Study 29336896 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with 0.3 mg ranibizumab
Number of subjects: 40
Study 26808532 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional weight loss of 1 kg/year
Number of subjects: 761
Study 24257718 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee high in chlorogenic acid (C-HCA)
Number of subjects: 10
Study 24257718 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee high in chlorogenic acid
Number of subjects: 10
Study 24257718 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee with regular amounts of chlorogenic acid (D-RCA)
Number of subjects: 10
Study 24257718 — intervention group
Group type: COMPARATOR
Intervention: High fructose diet
Number of subjects: 10
Study 21952267 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline physical activity
Number of subjects: 642
Study 21952267 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 642
Study 21952267 — intervention group
Group type: EXPERIMENTAL
Intervention: More social support for physical activity
Number of subjects: 642
Study 21952267 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 642
Study 21952267 — intervention group
Group type: EXPERIMENTAL
Intervention: Employees from the second worksite
Number of subjects: 642
Study 19410973 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-chain fructo-oligosaccharides (sc-FOS) 10 g daily for 36 days
Number of subjects: 14
Study 19410973 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 14
Study 17468494 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia
Number of subjects: 26
Study 17468494 — intervention group
Group type: COMPARATOR
Intervention: Propofol anaesthesia
Number of subjects: 26
Study 15470373 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (100 mg)
Number of subjects: 0
Study 15470373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11952442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal patent blue vital dye (PBV) sentinel node marking
Number of subjects: 20
Study 11952442 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PBV used)
Number of subjects: 20
Study 10753434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone injection (0.2 ml of a 4-mg/ml dexamethasone solution, 0.8 mg per injection)
Number of subjects: 500
Study 10753434 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection (control group)
Number of subjects: 500
Study 10753434 — intervention group
Group type: EXPERIMENTAL
Intervention: Various medical treatments (central vasodilators, vestibular suppressants, calcium channel blockers, anticholinergic drugs, anticonvulsant drugs, gingko biloba)
Number of subjects: 500
Study 7796901 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually experienced males
Number of subjects: 0
Study 7796901 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually experienced females
Number of subjects: 0
Study 7796901 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 0
Study 7796901 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 0
Study 2189668 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUE Test, Panel 2
Number of subjects: 808
Study 2189668 — intervention group
Group type: COMPARATOR
Intervention: Control method
Number of subjects: 808
Study 631966 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain xanthinol nicotinate
Number of subjects: 6
Study 631966 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release xanthinol nicotinate
Number of subjects: 6
Study 631966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30657348 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic HPV vaccination
Number of subjects: 0
Study 30657348 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-neutral HPV vaccination
Number of subjects: 0
Study 28170117 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary placement (Bioteque™ cup)
Number of subjects: 46
Study 28170117 — intervention group
Group type: COMPARATOR
Intervention: No pessary
Number of subjects: 46
Study 25881589 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment for 10 days followed by esomeprazole 20 mg bid for 46 days
Number of subjects: 356
Study 25881589 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20 mg bid therapy for 8 weeks (control group)
Number of subjects: 356
Study 25881589 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori positive uneradicated group
Number of subjects: 356
Study 25881589 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori negative group
Number of subjects: 356
Study 23962400 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 min brisk walking
Number of subjects: 41
Study 23962400 — intervention group
Group type: COMPARATOR
Intervention: Rest condition
Number of subjects: 41
Study 21919735 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring plus problem-solving counseling
Number of subjects: 29
Study 21919735 — intervention group
Group type: COMPARATOR
Intervention: Continuous glucose monitoring plus education
Number of subjects: 29
Study 19377796 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise at 90% of anaerobic threshold (AT)
Number of subjects: 48
Study 19377796 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise at 60% of anaerobic threshold (AT)
Number of subjects: 48
Study 19377796 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise at 110% of anaerobic threshold (AT)
Number of subjects: 48